Migraine disease per ICHD-3 criteria (for migraine participants) OR Healthy control patient
Exclusion criterion
Unstable medical condition or serious nervous system pathology
Pregnant, breastfeeding, lack of adequate birth control
Psychotic or manic disorder
Substance abuse in the prior 3 months
Use of classic psychedelics (e.g., psilocybin, LSD, mescaline) in the past 6 months
Use of cannabis or other THC products in the prior 2 weeks
Urine toxicology positive to drugs of abuse
The use of triptans (e.g., sumatriptan) or ditans (e.g., lasmiditan) more than twice weekly on average
Use of serotonergic preventive therapies (i.e., taken chronically; amitriptyline, fluoxetine, imipramine, cyproheptadine) in the past 6 weeks
Use of preventive or transitional treatments that produce spikes and waning of symptom relief (e.g., botulinum toxin, calcitonin gene-related peptide system targeting antibodies, peripheral nerve or ganglion blocks, chiropractic manipulation)
History of a bleeding disorder or are currently taking anticoagulants (e.g., warfarin, enoxaparin, dabigatran, apixaban).
Use of non-steroidal anti-inflammatory drugs (NSAIDs; e.g., ibuprofen, naproxen) in the 7 days before PET scan and 7 days after PET scan.
Clareo Health | Mechanistic Studies of Psilocybin in Headache Disorders
